Sildenafil Powder, For Suspension
Product Images NDC 27241-175

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 27241-175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafil 10mg Carton

FDA Label Image

Sildenafil 10mg

This is a package insert for a medication called Sildenafil, which is a suspension that contains 10 mg of the active ingredient sildenafil citrate per mL. Once reconstituted with 90 mL of water, each bottle contains 1.57 g of sildenafil citrate. The recommended dosage is not provided and the package is child-resistant. The medication should be stored below 30°C before and after reconstitution, either in the original package or in the refrigerator. The unused portion of the medication should be discarded 60 days after reconstitution. The medication is grape-flavored and produced by Ajanta Pharma USA Inc. in India. The insert provides a code number and NDC number.*

FDA Label Image

Sildenafil Figure3

FDA Label Image

Sildenafil_figure1 (Sildenafil Figure1)

FDA Label Image

Sildenafil_figure10.jpg (Sildenafil Figure10)

FDA Label Image

Sildenafil_figure11 (Sildenafil Figure11)

FDA Label Image

Sildenafil_figure12 (Sildenafil Figure12)

FDA Label Image

Sildenafil_figure2 (Sildenafil Figure2)

FDA Label Image

Sildenafil_figure4 (Sildenafil Figure4)

FDA Label Image

Sildenafil_figure5 (Sildenafil Figure5)

FDA Label Image

Sildenafil_figure6 (Sildenafil Figure6)

FDA Label Image

Sildenafil_figure7 (Sildenafil Figure7)

This is a table showing the drug interactions of different medications with Bosentan, Erythromycin, Oral Contraceptives, and Saquinavir. It provides recommendations for dosing adjustments and fold changes in AUC and Cmax. The 90% confidence intervals are also provided along with the change relative to Sildenafil alone. The table suggests that there is no benefit to exercise capacity when Sildenafil is added to Bosentan therapy. It is likely part of a larger document.*

FDA Label Image

Sildenafil_figure8 (Sildenafil Figure8)

This is a chart of recommended dose adjustments for various drugs when taken in conjunction with other drugs. It appears to be a medical reference for healthcare professionals. The chart contains information on potential interactions and the need for dosage adjustments. There is also some data given on the effects of certain drug combinations, including a study on the impact of adding bosentan therapy to an existing medication regimen.*

FDA Label Image

Sildenafil_figure9.jpg (Sildenafil Figure9)

FDA Label Image

Figurea (Sildenafil Figurea)

FDA Label Image

Figureb (Sildenafil Figureb)

FDA Label Image

Figurec (Sildenafil Figurec)

FDA Label Image

Figured (Sildenafil Figured)

FDA Label Image

Figuree (Sildenafil Figuree)

FDA Label Image

Figuref (Sildenafil Figuref)

FDA Label Image

Figureg (Sildenafil Figureg)

FDA Label Image

Structure (Sildenafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.